Computational protein variant design service using Catalophore cavity analysis, structural assessment, and sequence-based filtering. Innophore identifies promising mutation sites, ranks variants, and provides construct specifications and an analysis framework, enabling focused libraries for herbicide tolerance or detoxification. Wet-lab expression and testing are performed by the customer or an Innophore partner, with iterative design refinement based on experimental results.
Innophore offers a computational protein variant design and analysis workflow to support development of herbicide-tolerant or detoxifying enzymes. The service combines Catalophore cavity analysis, structural assessment, and sequence-based filtering to narrow large sequence spaces into focused, diverse libraries that balance predicted function, developability, and diversity. The result is a prioritized set of variants with construct specifications and an analysis framework linking each variant to experimental outcomes.
This offering is designed for organizations seeking to improve herbicide response, native activity, or protein stability in plant-relevant systems. Because computational methods alone cannot establish expression, folding, or herbicide tolerance, the workflow relies on a design-build-test-learn loop: the customer or an approved partner performs construct generation, parallel expression, and activity testing, while Innophore interprets the resulting data to refine designs and prioritize candidates for further validation.
Key features:
Workflow phases:
The Catalophore platform is established and has been used in enzyme and drug discovery collaborations. This specific variant design workflow for herbicide targets is at an early application stage, with feasibility to be assessed through agreed experimental readouts and success criteria. The proposed validation plan includes benchmarking current workflows, running a design-build-test-learn cycle, and confirming selected hits in plant-relevant systems before scale-up.
Innophore GmbH is a biotechnology company that provides a platform for enzyme and drug discovery through its proprietary Catalophore technology. Founded in 2017 in Graz, Austria, the company uses artificial intelligence and 3D point-cloud analysis to characterize protein binding sites rather than focusing on proteins alone. This methodology allows the company to conduct cavity-based searches across entire proteomes, offering capabilities that exceed traditional sequence or fold comparison methods. By transforming molecular structure into actionable data, Innophore supports research and development pipelines by identifying and optimizing protein candidates for applications in biotechnology, pharmaceuticals, and industrial processes.
The company's technology is utilized by global partners in sectors including healthcare, chemicals, and consumer products to accelerate R&D and improve safety. Innophore’s solutions enable clients to detect potential off-target interactions, reduce side effects, and optimize therapeutic or industrial enzymes more efficiently. The company gained significant industry recognition during the COVID-19 pandemic by rapidly identifying the SARS-CoV-2 main protease as a drug target. Innophore maintains collaborations with major technology partners, such as NVIDIA, to leverage advanced computational platforms like BioNeMo for large-scale structural modeling and drug discovery predictions, helping clients bring products to market with greater speed and precision.